- Home
- GSHR vs OABI Comparison
GSHR vs OABI Comparison
Compare GSHR & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSHR
- OABI
- Stock Information
- Founded
- GSHR 2024
- OABI 2012
- Country
- GSHR United States
- OABI United States
- Employees
- GSHR N/A
- OABI N/A
- Industry
- GSHR
- OABI Biotechnology: Pharmaceutical Preparations
- Sector
- GSHR
- OABI Health Care
- Exchange
- GSHR NYSE
- OABI Nasdaq
- Market Cap
- GSHR 205.8M
- OABI 172.5M
- IPO Year
- GSHR 2025
- OABI N/A
- Fundamental
- Price
- GSHR $10.06
- OABI $1.78
- Analyst Decision
- GSHR
- OABI Strong Buy
- Analyst Count
- GSHR 0
- OABI 3
- Target Price
- GSHR N/A
- OABI $7.00
- AVG Volume (30 Days)
- GSHR 4.7K
- OABI 1.1M
- Earning Date
- GSHR 01-01-0001
- OABI 08-07-2025
- Dividend Yield
- GSHR N/A
- OABI N/A
- EPS Growth
- GSHR N/A
- OABI N/A
- EPS
- GSHR N/A
- OABI N/A
- Revenue
- GSHR N/A
- OABI $26,744,000.00
- Revenue This Year
- GSHR N/A
- OABI N/A
- Revenue Next Year
- GSHR N/A
- OABI $44.34
- P/E Ratio
- GSHR N/A
- OABI N/A
- Revenue Growth
- GSHR N/A
- OABI 27.07
- 52 Week Low
- GSHR $9.97
- OABI $1.22
- 52 Week High
- GSHR $10.25
- OABI $4.96
- Technical
- Relative Strength Index (RSI)
- GSHR N/A
- OABI 64.73
- Support Level
- GSHR N/A
- OABI $1.35
- Resistance Level
- GSHR N/A
- OABI $1.59
- Average True Range (ATR)
- GSHR 0.00
- OABI 0.10
- MACD
- GSHR 0.00
- OABI 0.07
- Stochastic Oscillator
- GSHR 0.00
- OABI 95.73
About GSHR GESHER ACQUISITION CORPORATION II ORD USD0.0001 CL A
Gesher Acquisition Corp II is a blank check company.
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.